Full-text articles in English of randomized controlled trials or patient cohort studies were included. The main eligible criteria were as following: (1) studies in which patients were with newly diagnosed MCL and received no prior treatment; (2) studies in which the association between MRD and survival outcomes was reported; (3) studies from which the data of interest could be extracted. When the studies reported data from the same patient cohort or the patient cohort was overlapping, the study with most updated and complete data would be included. Outcomes of interest were progression-free survival (PFS) and overall survival (OS). Data were analyzed for PFS and OS grouped by MRD detection time. Two investigators (YZ and HZC) worked independently to assess the eligibility of studies. If there was any disagreement, studies would be re-assessed by the third investigator (YXT).

Note: The content above has been extracted from a research article, so it may not display correctly.



Q&A
Please log in to submit your questions online.
Your question will be posted on the Bio-101 website. We will send your questions to the authors of this protocol and Bio-protocol community members who are experienced with this method. you will be informed using the email address associated with your Bio-protocol account.



We use cookies on this site to enhance your user experience. By using our website, you are agreeing to allow the storage of cookies on your computer.